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Insufficient angiogenesis remains a major hurdle in current bone tissue engineering strategies. 
An extensive body of work has focused on the use of angiogenic factors or endothelial 
progenitor cells. However, these approaches are inherently complex, in terms of regulatory and 
methodologic implementation, and present a high cost. In this sense, simpler and more cost 
effective alternatives are awaited. We have recently demonstrate the potential of electrospun 
poly(lactic acid) (PLA) fiber-based membranes, containing calcium phosphate (CaP) ormoglass 
particles, to elicit angiogenesis in vivo, in a subcutaneous model in mice by fast calcium ion 
release. Here we have devised an injectable composite, containing CaP glass-ceramic particles 
dispersed within a HPMC matrix, with the capacity to release calcium in a more sustained 
fashion combined with the aforementioned fiber-based mats acting as enevelope. We show that 
by tuning the release of calcium, in vivo in a rat bone defect model, we could improve both 
bone formation and increase angiogenesis. This methodology allows to integrate two 
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1. Introduction 
Current bone regeneration approaches still face a wide range of limitations that in combination 
to the increased incidence of bone pathologies linked to the general population aging profile it 
continues to pose an important health challenge. Present regeneration approaches are focused 
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on three main strategies: 1) autologous bone grafts that, although the gold standard for bone 
regeneration and the most common approach, implies a two stage time consuming surgical 
procedure, that requires patients in general good health and is often associated with significant 
morbidity, post-operative pain, hypersensitivity, infection and paresthesia [1-4]; 2) allogeneic 
bone grafts, often associated with immunogenic and infection risks [5]; and 3) bone substitutes, 
based on biodegradable polymers and/or synthetic ceramics,  increasingly being studied as bone 
tissue engineering material as they can be established as an off-the-shelf clinical product [6]. 
This last approach, although with great potential to satisfy clinical need, has shown insufficient 
vascularization and osteointegration, when in the absence of autologous cells and/or 
proangiogenic factors [7]. Indeed, attempts to stimulate neovascularization, by the use of 
recombinant protein, angiogenic growth factors gene transfer or endothelial cells have been 
proposed, however often associated with problems regarding the delivery and duration of 
exposure to the growth factors and with the survival of endothelial cells [7]. Additionally, due 
to inherent risks, the use of growth factors and autologous cells presents additional regulatory 
hurdles, particularly relevant in some cases of bone repair post cancer resection [8]. Hence, in 
order to fulfill the promise of bone tissue engineering the problematic of neovascularization, 
inside the implanted constructs, has to be solved in order to reach the bedside. This drawback 
is particularly relevant in large bone defects, where the amount of oxygen required for cell 
survival is limited to a diffusion distance between 150-200 µm from the supplying blood vessels 
[9]. Nonetheless, in view of a broad clinical application, the establishment of off-the-shelf 
strategies may prove beneficial and reduce regulatory issues. As such, the use of synthetic 
polymeric matrices, that can be readily engineered and custom designed, may show the future 
for new bone therapeutic approaches.  
We have recently demonstrated the potential of electrospun poly(lactic acid) (PLA) fiber-based 
membranes, containing calcium phosphate ormoglass (CaP) particles, to elicit angiogenesis in 
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vivo, in a subcutaneous model in mice [10]. These CaP particles with capacity to release 
bioactive calcium ions, in a controlled fashion, are an alternative cost effective approach in 
order to achieve ready-to-use bone substitutes. Based on the observation that sudden increased 
local concentration of calcium (Ca2+) ions could induce the migration, maturation and 
organization of endothelial progenitors [11], we could demonstrate in vivo that these materials 
could elicit the local expression of angiogenic factors, associated to a chemotactic effect on 
macrophages, and sustain angiogenesis into the biomaterial [10]. 
On the other hand, calcium phosphate glass ceramic are a very promising alternative for a more 
progressive ion release rate as crystalline phases use to degrade slower than glassy ones 
[Navarro et al. Biomaterials. 2004 Aug;25(18):4233-41]. Our hypothesis is based on the slower 
and longer healing of the inner part of the bone tissue and thus the required Ca2+ stimulation 
should be slower and more sustained. 
Here we evaluated the use of a sol-gel prepared CaP glass-ceramic in an orthotopic model, in a 
condylar defect in rat, to sustain both bone repair and angiogenesis. We tested different 
calcination temperatures, in order to tune Ca2+ release profiles, formulated them as an injectable 
composite and associated it with a PLA/ormoglass contention membrane.  
 
2. Materials and Methods 
2.1. Reagents 
Unless mentioned otherwise, all reagents were obtained from Sigma-Aldrich and were of 
analytical grade. 
2.2. Scaffolds fabrication and characterization 
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Sol-gel alkoxide precursor solutions were prepared by refluxing them in proper solvents, except 
Ti tetraisopropoxide was commercially obtained (ALFA AESAR, 97%) and diluted in absolute 
ethanol. Ca and Na precursor solutions were prepared by refluxing metallic Ca and Na in 2-
methoxyethanol. P precursor solution was obtained by refluxing P2O5 in absolute ethanol. 
2.2.1. Electrospun PLA mats with embedded NP 
CaP ormoglass NPs were prepared by a partial hydrolyzed alkoxides sol-gel method with a 
composition of 44.5:44.5:6:5 CaO:P2O5:Na2O:TiO2 molar ratio, following a previous report  
[12]. After mixing Ca, Na an Ti precursor solutions in the proper molar ratio in inert 
atmosphere, a catalyst with a composition related to Ti (Ti:H2O:NH3:EtOH 1:60:0.3:12) was 
added at 4ºC at 2 ml/h using an infusion pump. Afterwards, P precursor was similarly added at 
4ºC and 1 ml/h flow. The mix turned from dark brown to clear orange and it was subsequently 
hold at 70ºC during 4 days for aging and allow the formation of NPs. They were finally 
collected and washed with absolute ethanol by centrifugation and dried at 90ºC in the oven.  
Nanofiber mats were prepared as previously described [10]. Briefly, PLA nanofibers loaded 
with 20% (w/w) of CaP ormoglasses (labelled as PLA CaP) were prepared by the ultrasonic 
dispersion of the nanoparticles in a 4% (w/v) PLA (Purasorb PLDL 7038, inherent viscosity 
midpoint 3.8 dl/g, molecular mass ≈ 850,000 Da) solution. Slurries were electrospun at 8.000V, 
150 mm distance tip-collector and at 1200 rpm rotary collector speed. 
2.3. Nanostructured G8 glass-ceramic injectable gels fabrication 
To prepare the glass-ceramic material Ca, Na and Ti precursor solutions were mixed in inert 
atmosphere in the proper molar ratio, similarly to previous process. P precursor solution was 
then added at 4ºC and a rate of 2.5 mL/h using an infusion pump. Then, an acid aqueous catalyst 
with a Ti molar relation of Ti:20 H2O:0.1 HCl:5 isopropyl alcohol was added at a rate of 1 mL/h 
and 4ºC. The mix was sealed and left to rest for 24 hours at room temperature and then heated 
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at 80ºC for 3 days. The resulting liquid part was poured and eliminated, and the solid gel heated 
at 120ºC for 12 hours at air. The resulting powder was grounded and hold to a thermal treatment 
at 500, 540, 570 or 610ºC  (labelled as CaP 500, CaP 540, CaP 570 and CaP 610) for 5 hours. 
The final powder was milled and sieved to obtain sintered nanoparticles agglomerates smaller 
than 40 µm. 
(Hydroxypropyl)methyl cellulose (HPMC, Mn 90 000 Da, Sigma) was dissolved in Phosphate 
buffer saline (PBS) to a final concentration of 2% (w/v) and sterilized by autoclaving. In order 
to formulate the composite gel, 40% (w/v) of CaP particles were dispersed in the HPMC gel. 
Both constructs, produced as stated in sections 2.2 and 2.3, were then combined for the in vivo 
assays. 
2.4. Calcium release, FE-SEM characterization and chemical composition. 
Calcium release from the glass-ceramics powders was measured using an ion selective 
electrode. 15 mg of glass or glass-ceramic powder samples were bathed in 750 μL of 0.01 M 
HEPES buffer solution and incubated at 37°C. Bathing fluid was removed periodically (every 
3-4 days) for a period of 36 days and pH and calcium ions were measured in the removed 
solution. pH was measured with a Crison GLP22 (Crison, SPAIN), while electrical potential of 
the solution was measured with a combined calcium selective polymer-membrane electrode 
(Metrohm AG, Herisau Switzerland). Electrical potential values read from the solution were 
compared to measurements from calibration solutions to determine calcium concentrations of 
the samples. 
Micro- and Nano-morphology was measured using an Ultra-High Resolution Field Emission 
Scanning Electron Microscopy (Nova Nano SEM-230; FEI Co., Netherlands), operating at 5.00 
Kv and coating the samples with an ultra-thin layer of carbon to make them conductive. 
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Material’s composition was assessed using an Energy Dispersive X-ray Spectrometer (EDS, 
Quanta 200 XTE 325/D8395; FEI Co.). Materials were also coated with a thin layer of carbon 
before analysis. 
2.5. Glass transition temperature and simultaneous thermogravimetric (TGA) and 
differential thermal analysis (DTA).  
Glass transition temperature was measured on a Q20 differential scanning calorimeter (TA 
instruments, USA). A heating rate of 10°C/min to 600°C was used. Simultaneous 
thermogravimetric and differential thermal analysis of the sol-gel sample was executed on a 
Netzsch STA 409 C/CD instrument (NETZSCH-Gerätebau GmbH, Germany). A heating rate 
of 10°C/min to 900°C was used.  
2.6. X-ray diffraction 
XRD was measured on a PANalytical X’pert PRO MPD Alpha1 powder diffractometer. 
Patterns were collected from 2θ = 4.2 to 80° with a step size of 0.017° and a measuring time of 
50 seconds per step.  
2.7. Organic Elemental Analysis 
Powder glass-ceramic samples were analyzed after heat treatment to determine residual carbon 
using a Carlo Erba Instruments Thermo Flash 2000 (Carlo Erba, Milan, Italy). This method is 
based on a Gas chromatography after total decomposition and oxidation  of the sample at high 
temperature (~1800ºC). For that purpose, 100mg samples were used.. 
2.8. Cell culture 
Human progenitor-derived endothelial cells (PDECs) were obtained as previously described 
[13]. Briefly, human umbilical cord blood from healthy donors (between 20 and 35 years) were 
diluted with one part of PBS, 2% (v/v) fetal calf serum (FCS) and 2 mM ethylene diamine 
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tetraacetic acid (EDTA), and applied to a density gradient centrifugation in Histopaque® 
solution (1.077 g.mL−1). Mononuclear cells were recovered from the buffy coat, washed several 
times with PBS and cultured in endothelial cell growth medium-2 (EGM-2; Lonza-Verviers, 
France) containing all kit supplements and 5% (v/v) FCS (GIBCO Life Technologies, 
Karlsruhe, Germany), on collagen-coated 12-well plates (collagen type I from rat tail, BD 
Biosciences) and at 5x107 cells per cm2. At day 4, non-adherent cells were removed and medium 
was refreshed every other day. After 2–3 weeks, cobblestone-like morphology colonies were 
harvested, using 0.25% (w/v) trypsin–EDTA (GIBCO) and subcultured in fresh collagen-
coated dishes. Cells were expanded over several passages, using standard cell culture 
procedures. 
2.9. In vitro evaluation 
Twenty-four hours prior, PDECs were seeded on 24 well plates at 20x103/cm2 and cultured 
using 500 μL of endothelial cell growth medium-2 (EGM-2; Lonza-Verviers, France). Then, 
50 μL of HPMC gels, containing 40% (w/v) of CaP particles sintered at 540 or 570 degrees, 
were placed inside a 0.4 μm pore transwell (Corning, EMEA, France) and set in contact with 
the cell culture medium. At designated time points cells were processed for viability assay or 
cells culture medium was assessed for VEGF quantification. 
2.10. Cell viability assessment 
Cytotoxicity assessment on human PDECs was performed according to the standard ISO/EN 
10993, part 5, guidelines and using the neutral red assay. Briefly, 24 hrs post exposure to the 
HPMC gels, through the transwell inserts, and the colorimetric neutral red assay was performed 
according to established protocols [14].  
2.11. VEGF secretion evaluation 
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In order to assess the capacity of the different materials to induce the secretion of vascular 
endothelial growth factor (VEGF), the cell culture medium of PDECs cultured on the different 
materials for 4 days was recovered, snap frozen and kept at -80ºC until further use.  Secreted 
VEGF was evaluated by ELISA assay using a commercial kit (human VEGF ELISA, #DVE00, 
R&D Systems, USA) following the manufacturer's instructions.  
2.12. Animal procedures 
As an initial model to assess the capacity of the developed materials to sustain bone repair we 
implanted them in a bone defect model in rats, condylar defect. All the procedures for rat 
handling were based on the principles of Laboratory Animal Care formulated by the National 
Society for Medical Research and approved by the Animal Care and Experiment Committee of 
University of Bordeaux, Bordeaux, France. Experiments were carried out in accredited animal 
facilities following European recommendations for laboratory animal care (directive 86/609 
CEE of 24/11/86). 
Medial holes, 4 mm diameter and 6 mm depth were created in both left and right femoral 
condyles of Wistar rats weighing 200-250 g (Charles River Laboratories, France). Bone pieces 
were removed from the defect, and the holes were rinsed with physiological solution (NaCl 0.9 
% (w/v)) before injecting the Hydroxypropyl Methylcellulose (HPMC) gel, containing or not 
40% (w/v) of calcium phosphate particles, sintered at two different temperatures (i.e. 540 or 
570 ºC). The PLA membrane, containing or not 20% (w/w) NPs (as previously described in 
Oliveira et al. Acta Biomaterialia 29(), 435-445) was used to constrain the gel inside the defect 
and to start vascularization on the defect side. At 3 and 6 weeks animals were sacrificed by CO2 
inhalation and femoral bones were recovered for histologic, immunohistochemistry and μCT 
evaluation. Six independent materials were implanted per tested material and per time point. 
2.13. X-ray microtomography and analysis 
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Micro-CT was performed on Explore Locus SP X-ray m-CT devices (General Electric, 
Milwaukee, WI) ex vivo with a source voltage of 80 kV and a current of 60 mA to obtain a 15 
mm resolution from 900 X-ray radiographs with an exposure time of 3000 ms. After scanning, 
cross-sectional slices were reconstructed and three-dimensional analysis were performed using 
eXplore MicroView software (General Electric Healthcare, Milwaukee, WI). Reconstruction 
of the region of interest was performed after correction of the center of rotation and calibration 
of mineral density. Each scan was reconstructed using the same calibration system to 
distinguish bone and air. Bone volume (BV) per total volume (TV) was determined for each 
sample.  
2.14. Histological analysis 
The femoral and tibial bones were recovered, fixed with 4% (w/v) paraformaldehyde for 48 hrs 
at 4°C and then demineralized (Microdec, Diapath, France), dehydrated and embedded in 
paraffin. Eight microns sections were cut and stained with Masson’s Trichrome for osteoid 
staining, using standard protocols, and observed under a photomicroscope (Nikon eclipse 80i, 
The Netherlands).  
2.15. Immunohistochemistry analysis 
Immunohistochemistry for CD31 was performed as follows. Eight-micron paraffin sections 
were cut, deparafinized, rehydrated using ethanol gradients and placed in PBS. Antigen 
recovery was performed using a proteinase K (Roche, France) digestion procedure and then 
endogenous peroxidase was quenched using 3% (v/v) hydrogen peroxide for 5 min at room 
temperature (RT). Tissues were blocked with 2% horse serum, in PBS, for 30 min at RT. 
Primary antibody against CD31 (NB100-2284, Novus Biologicals, Bio-Techne, France) was 
used at 1:100 in 2% (w/v) BSA in PBS, and incubated overnight at 4°C. After two washes with 
PBS, the anti rabbit Impress kit (VectorLabs, USA) was used according to the manufacturer's 
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instructions. Specific staining was obtained using the 3,3’-diaminobenzidine staining solution 
(VectorLabs, USA). Counterstaining was performed using Mayer’s haematoxylin. Samples 
were then mounted using Pertex medium (Sigma). Sample imaging was performed using a 
microscope (Nikon Eclipse 80i) equipped with a digital camera (Nikon Dxm 1200C). Sample 
analysis was performed at three different sample positions and a total of six animal samples 
were assessed per time point and condition. For vessel quantification the total number of micro 
vessels was determined and normalized to the area of the defect. 
2.16. Statistical analysis 
Using the Graphpad Prism 5.0 software, a D’Agostino and Pearson omnibus normality test was 
used in order to test if data obeyed to a Gaussian distribution. Statistically significant 
differences between several groups were analyzed by the non-parametric Kruskal-Wallis test, 
followed by a Dunns post-test. The non-parametric Mann-Whitney test was used to compare 
two groups. A p value lower than 0.05 was considered to be statistically significant. 
 
3. Results 
3.1. Biomaterial synthesis and characterization 
Differential thermal analysis (DTA) is a powerful tool when considering sol-gel glasses 
analysis, due to the ability to evaluate the chemical changes that occur during the calcination 
steps. Figure 1A displays the DTA plot for the sol-gel material, and in this representation, 
exothermic reactions correspond to a downward peak on the y-axis. The gravimetric portion of 
this plot is characterized by a series of downward steps, as materials are burned away during 
calcination. These downward steps correspond with peaks in the thermometric plot, signifying 
a chemical change in the sample. The major events in the sol-gel material include a small mass 
loss and exothermic peak at around 130°C, which corresponds to the loss of residual water from 
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the material, and then two endothermic peaks at about 250 and 320°C as the organic residues 
are eliminated. Indeed, and as observed in Table 1, residual carbon content was below 0.1%, 
consistent with the DTA results. Additionally, glass transition temperature (Tg) was 480ºC in 
both cases and composition, measured by energy dispersive X-ray spectroscopy (EDS), was as 
expected (Table 1). In order to analyze the formation of the crystalline phase after the 
calcination of the sol-gel material, an X-ray powder diffraction (XRD) evaluation was 
performed. Figure 1B shows how the final amount of crystallization within the material is 
closely related to the temperature of calcination. Here, all sol-gel samples are compared at the 
4 different temperatures treated. Corresponding to the step-wise increase of calcination 
temperature, each subsequent material exhibits an increase in crystallinity. The sample calcined 
at 500 ºC had a completely amorphous behavior, and presented a dark grey color associated to 
a high carbon content. As such, this sample formulation was discarded from further studies. 
The one calcined at 540°C still contains a large amorphous phase, while the powder calcined at 
610°C is completely crystalline. Compounds visible in the sol-gel glass ceramic samples 
include pyrophosphates, both α (α-Ca2P2O7, JCPDS 9-345) and β (β-Ca2P2O7, JCPDS 9-346), 
as well as a calcium metaphosphate (δ-Ca(PO3)2, JCPDS 9-363) and a singular sodium-titanium 
phosphate NaTi2(PO4)3 (JCPDS 84-2008) (Figure 1B).  
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Figure 1- A) Differential thermal analysis (DTA) plot of the sol-gel material. DTA is 
represented by the solid line with the left axis, while the mass change trace is displayed by a 
dotted line and corresponds to the right axis. B) X-ray powder diffraction (XRD) and phase 
composition comparison of the sol-gel materials calcined at different temperatures (°C) a) 610, 
b) 570, c) 540 and d) 500 ºC. 
Figure 2A displays the calcium ion release results for the material, in which total ion release is 
summed over time. Glass-ceramic particles demonstrated a linear release rate, over the entire 
time frame investigated. Additionally, the plot shows that with increased sample calcination 
temperature there is a decrease in the solubility of the ceramic, due to the increased crystallinity 
of the final product. Respectively, the three sol-gel samples CaP540, CaP570 and CaP610 
exhibited linear release rates of 0.065, 0.054 and 0.029 mM/day.  
As observed in Figure 2B, pH remained very closed to physiological one in the glass-ceramic 
environment, for the 3 tested CaPs. Nonetheless, due to the slow release kinetics of CaP 610 
sample, we focused on the CaP540 and CaP570 bioglass formulations in the following studies. 
Figures 2A and 2B, show the micrography of both CaP540 and CaP570 showing a nanoscaled 
crystal particle sizes connected by sintering. 
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 Figure 2- A) Ca2+ release and B) pH evaluation from samples calcined at 3 different 
temperatures and the G5 standard previously reported. C) and D) are representative 
micrographies by FE-SEM of nanostructured agglomerates resulting from the glass-ceramic 
fabrication. 
Table 1- Glass transition temperature (Tg), Carbon final content, and oxide based composition 
of the glass ceramic calcined at 540 and 570ºC (average±SD). 
 
Tg Carbon Content 
(at%) CaO 
P2O5 Na2O TiO2 
G8-540 
480ºC 
0.097 ± 0.006 45.3±2.9 44.1±2.4 3.3±1.6 7.2±1.8 
G8-570 0.080 ± 0.008 45.6±1.2 42.9±1 3.0±0.5 7.7±0.4 
 
3.2. In vitro evaluation 
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In view of the application of these matrices to bone tissue regeneration and to support 
angiogenesis we initially tested the influence of the composite biomaterial over human PDECs 
cell viability. As observed in figure 3A, no significant differences could be observed for both 
CaP formulations, in relation to the control. Additionally, and as means to assess the impact of 
the composite formulation over the expression of VEGF we performed an ELISA assay to 
determine the VEGF secretion by PDECs after 4 days of exposure, using a transwell system. 
As observed in figure 3B a significant increase of VEGF secretion was observed for the 540 
ºC CaP composite formulation, in relation with the control.  
 
Figure 3- A) Percent cell viability, as measured by the neutral red assay, of human progenitor-
derived endothelial cells (PDECs) exposed for 24 hr to (Hydroxypropyl) methyl cellulose 
(HPMC) gels containing 40% (w/v) of calcium phosphate particles (CaP), sintered at two 
different temperatures (i.e. 540 or 570 ºC) and normalized in relation to the control 
(Average±SD, n=8, * and NS denotes p<0.05 or non significant, respectively). B) 
Quantification of vascular endothelial growth factor (VEGF) expression by PDECs cultured 
with exposure, during 4 days, to HPMC gels containing 40% (w/v) of CaP, sintered at 540 or 
570 ºC (n=4, average±SD; * and NS denotes p<0.05 or non significant, respectively). 
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 3.3. In vivo evaluation 
In view of determining the capacity of the developed composites to sustain bone repair we 
focused on a bone defect model in the rat condyle. For this purpose, the two developed 
composite injectable hydrogels, based on sintered CaP at 540 or 570 ºC, were placed in the 
defect and covered with an electropsun PLA membrane (containing or not 20% (w/w) of CaP 
particles) previously reported [10]. Bone regeneration was evaluated at 3 and 6 weeks post-
implantation using micro CT based 3D reconstruction and histologic evaluation. As observed 
in figure 4A micro CT imaging shows improved calcified tissue formation for the composite 
formulations containing CaP materials, in relation to HPMC and PLA alone, and at both time 
points evaluated. These results are confirmed by micro CT quantification of the mineral 
volume/total volume ratio (BV/TV) for the explanted femurs (Figure 4B).  A significant 
improvement on BV/TV was observed for the HPMC 540, at 3 weeks, in relation with HPMC 
PLA alone. Also, at 6 weeks post implantation both formulations containing CaP particles (i.e. 
HPMC 540 and 570 with PLA membrane 20% Nps) showed significant improved BV/TV, 
when compared with HPMC PLA alone. 
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 Figure 4- A) Micro-CT representative evaluation of bone formation inside the condylar bone 
defects when filled with (Hydroxypropyl) methyl cellulose (HPMC) gels containing 40% (w/v) 
of calcium phosphate particles (CaP), sintered at two different temperatures (i.e. 540 or 570 
ºC), and covered with PLA, alone, or containing 20% CaP particles, at 3 and 6 weeks post 
implantation. B) Quantitative assessment of Bone volume/total volume (BV/TV), by μ-CT 
evaluation, inside the condylar bone defects when filled with HPMC gels containing 40% (w/v) 
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of CaP particles, sintered at 540 or 570 ºC, and covered with PLA, alone, or containing 20% 
CaP particles, at 3 and 6 weeks post implantation. (Average±SD, n=6, **,  *** and NS denote 
p<0.01, p<0.001 and non significant, respectively). 
Micro-CT evaluation was then complemented using histologic evaluation. As observed in 
Figure 5, significant osteoid tissue formation could be observed in the case of the formulations 
containing CaP particles, at both 3 and 6 weeks, and consistent with the results obtained from 
micro-CT analysis. Also, one can observe that for the two formulations containing CaP particles 
an increased formation of osteoid tissue (red staining inside the defect) was formed, associated 
with the deposition of a collagenous matrix (green staining inside the defect, when compared 
with HMPC and PLA alone (Figure 5).  
 
 
Figure 5- Masson’s Trichrome staining of histological sections of the condylar bone defects 
when filled with (Hydroxypropyl) methyl cellulose (HPMC) gels containing 40% (w/v) of 
calcium phosphate particles (CaP), sintered at two different temperatures (i.e. 540 or 570 ºC), 
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and covered with PLA, alone, or containing 20% CaP particles, at 3 and 6 weeks post 
implantation  (scale=1000μm). 
 
In view of evaluating the impact of the different formulations, containing CaP particles sintered 
at two distinct temperatures (i.e. 540 and 570 ºC), on the formation of angiogenesis, we 
performed an immunohistochemistry for CD31 at 3 and 6 weeks post implantation in a rat 
condylar defect model. As observed in Figure 6, CD31 immunostaining revealed the existence 
of vessels inside the defect at both 3 and 6 weeks post implantation. The vessel distribution was 




 Figure 6- CD31 immunohistochemistry of histological sections of the condylar bone defects 
when filled with HPMC and covered with PLA alone (A1, A2 and D1, D2), or containing CaP 
particles sintered at 540 (B1, B2 and E1, E2) or 570 ºC (C1, C2 and F1, F2) and covered with 
PLA containing 20% CaP particles, at 3 (A-C) and 6 (D-F) weeks post implantation  
(scale=1000μm for A1-F1 or scale=100μm for A2-F2). Blood vessels identified by arrows. 
 
As means to quantify the influence of both the presence of CaP particles within the composite 
material and of the CaP sintering temperature on angiogenesis we performed vessel 
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quantification inside the defect. As observed in Figure 7, and although no significant 
differences could be observed at 3 weeks, at 6 weeks post implantation a significant increase 
for vessel density could be observed for the defects implanted with HPMC containing CaP 
particles sintered at 540ºC and covered with PLA membranes, containing CaP, in relation to 
HPMC and PLA alone.  
 
 
Figure 7 – Quantification of vessel density inside the condylar bone defects when filled with 
HPMC and covered with PLA alone, or containing CaP particles sintered at 540 or 570 ºC and 
covered with PLA containing 20% CaP particles, at 3 and 6 weeks post implantation 





 4. Discussion 
Autologous bone grafts are still the gold standard when considering the regeneration of bone 
defects. Nonetheless, they are associated with several drawbacks, including limited graft 
availability, increased risk of infection and significant morbidity at the donor site [15]. In this 
sense bone tissue engineering approaches have been proposed as promising alternatives, but in 
spite of tremendous effort and important advances achieved in the last two decades they have 
not yet fulfilled their promise [16]. One of the major problematic associated with the efficient 
translation of bone tissue engineering is the inefficient vascularization of both the implanted 
constructs and the defect site [6]. In this regard, growing interest has been focused on the 
development of bioactive biomaterials that can modulate the angiogenesis process, during bone 
tissue regeneration. Recently, we have shown the potential of electrospun poly(lactic acid) 
(PLA) fiber-based membranes, containing calcium phosphate ormoglass (CaP) particles, to 
elicit angiogenesis in vivo, in a subcutaneous model in mice [10]. In order to apply this principle 
to a bone regeneration scenario, here we developed a two component biomaterial approach: 1) 
a contention membrane of electrospun PLA, containing 20% (w/w) of CaP particles, that was 
previously optimized [10]; and 2) an injectable gel composed of a new generation of CaP 
ormoglasses, dispersed at 40% (w/v) in a HPMC gel.  
HPMC is a derivate polymer of cellulose that has shown to exhibit suitable biological 
characteristics and that has already been used for the formulation of injectable biomaterial 
matrices, containing calcium phosphate ceramics [17-19]. 
Our first approach was to optimize the conditions of CaP particle production, focusing on their 
ration of glass/ceramic character, in order to tune their degradation rate and obtain a sustained 
calcium release profile. As expected, a significant mass loss was observed during the first step 
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of calcination, up to 350ºC, where the material lost nearly 40% in terms of mass. These results 
were in agreement with previous reports of sol-gel synthesis of phosphate glasses [20, 21], 
where at 350ºC the vast majority of the water and extraneous organic material can be 
eliminated, as shown in Table 1. 
The use of different calcination temperatures, over the Tg (Table 1), shows the appearance of 
different crystal phases (Figure 1B), such as pyrophosphates and the polymorph γ of the 
tricalcium phosphate. These compounds, as well as the notable absence of calcium-phosphates, 
have shown to be characteristic of phosphate-based sol-gel and melted glasses [22]. 
Additionally, the presence of a NaTi2(PO4)3 peak shows that in spite of the small quantity used, 
an efficient inclusion of both titanium and sodium, into the crystalline network, was achieved. 
Also, and although the ratios of these compounds remain similar throughout the heating 
process, higher processing temperature show to favor the β-calcium pyrophosphate phase. As 
previously mentioned, the aim was to achieve a blend of both glassy and crystalline CaP 
ormoglass, as such and due to the high crystallinity of the formulation calcinated at 610ºC, this 
last was discarded from further studies.  
One of the limitations regarding glassy materials resides on their fast degradation, after 
immersion in fluid, and therefore accelerated release of ions in the first several days, before 
flattening out to a relatively slow release rate [23]. Conversely, we show that by introducing a 
nanocrystalline phase we could achieve a constant calcium release rate. This approach allows 
to tune the release profiles, while maintaining the advantageous zero-order release. 
Additionally, and in contrast to glassy calcium phosphates materials that usually exhibit a 
dramatic and immediate pH drop, due to the burst release mechanism [23], our approach shows 
little pH variation, over the entire time course. This presents an added value for these materials 
as significant acidifications has shown to induce osteoblast cell death and pro-inflammatory 
cytokine release by osteoblastic cells [24].  
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Nonetheless, the thermic process used, necessary to eliminate organics and nucleate the crystal 
nanophases, shows particle sintering due to the high atomic diffusion. Alternative processes 
can be used to avoid this issue such as the modification of the thermodynamic stability by 
altering some experimental conditions or using methods such as spray pyrolysis to avoid the 
physical contact among particles during the phase’s growth.  
Following the establishment of two ormoglass formulations, calcined at 540 and 570ºC, and 
based on previous reports [18, 19], we formulated them at 40% (w/v) in a 2% (w/v) HPMC gel. 
In vitro tests confirm their lack of toxicity for PDECs, under the test conditions, and show a 
dependence of the calcination temperature on their capacity to elicit VEGF secretion. The 
HPMC gels containing 40% (w/v) of CaP, sintered at 540 showed the better performance in 
terms of VEGF secretion. This correlates well with our previous studies were it was 
demonstrated that Ca2+ release from ormoglass particles, in the range of 0.6 - 1 mM, induced 
expression of VEGF gene and protein secretion [10, 25]. 
Then, focusing on the application of these composites for bone repair we evaluated their 
capacity to sustain bone repair in a condylar defect model in rat. Significant improvement in 
terms of BV/TV was observed for the 540 formulation, at 3 weeks, and for both 540 and 570, 
at 6 weeks, in relation to the vehicle alone. These results are in line with the Ca2+ release kinetics 
of both the 540 and 570 formulations, where a faster Ca2+ release (i.e. 540) shows to favor a 
faster bone repair, evident by micro CT analysis and by the formation of osteoid tissue. Previous 
studies have indeed shown that elevated Ca2+ levels could promote the recruitment of bone 
marrow progenitor cells in vivo [26, 27], regulate both bone morphogenetic protein and type I 
collagen synthesis by osteoblastic cells [28] and modulate the osteoinduction of mesenchymal 
stem cells [29]. Additionally, we and others have shown that bioactive glasses sustain the 
expression of proangiogenic cytokines and indirectly induce angiogenesis in vitro [25, 30] and 
in vivo [10]. The in vitro mechanism of action of these bioactive ormoglasses has been 
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associated with the degradation of the CaP, leading to the release of physiologically relevant 
amounts of ions in the extracellular media [30-32]. In vivo, we have recently shown that, 
correlated with the Ca2+ release there was a significant expression of angiogenic factors, 
associated to a chemotactic effect on macrophages, what finally showed a significant increase 
of angiogenesis into the biomaterial [10]. 
As extracellular calcium has shown important roles both on proliferation, chemotaxis and 
differentiation of cells, and as elevated calcium levels have been described in the extracellular 
fluids of tissues suffering remodeling [33], namely bone, it has been proposed that increased 
calcium levels may act as paracrine regulators for various cellular functions.  
Indeed, in the same line of we have recently shown [10], the injectable composite, containing 
40% of ormoglasses cancined at 540ºC, shows a significant improvement in terms of 
angiogenesis. We assume that due to its faster Ca2+ release kinetics, in relation to the 
ormoglasses sintered at 570 ºC, it enables the release of Ca2+ in a range suitable for both 
improved osteogenesis and angiogenesis. 
Altogether, one can assume that local elevated calcium levels may induce the recruitment of 
cells able to favor both a pro angiogenic milieu and to sustain bone formation.  This approach 
allows in a simple and cost effective manner to address both the promotion of bone repair and 
to sustain angiogenesis. 
 
5. Conclusions 
We have developed an injectable composite, containing a CaP glass-ceramic dispersed within 
a HPMC matrix, with the capacity to release calcium in a controlled way. We show that by 
tuning the release of calcium, in vivo, we could improve both bone formation and also increase 
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angiogenesis. This methodology allows integrating two fundamental processes for bone tissue 
regeneration while using a simple, cost effective and safe approach.  
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